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Abstract
Selective androgen receptor modulators (SARMs) have been proposed as therapeutics 
for women suffering from breast cancer, muscle wasting or urinary incontinence. The 
androgen receptor (AR) is expressed in the uterus but the impact of SARMs on the 
function of this organ is unknown. We used a mouse model to compare the impact of 
SARMs (GTx-007/Andarine®, GTx-024/Enobosarm®), Danazol (a synthetic androstane 
steroid) and dihydrotestosterone (DHT) on tissue architecture, cell proliferation and 
gene expression. Ovariectomised mice were treated daily for 7 days with compound or 
vehicle control (VC). Uterine morphometric characteristics were quantified using high-
throughput image analysis (StrataQuest; TissueGnostics), protein and gene expression 
were evaluated by immunohistochemistry and RT-qPCR, respectively. Treatment with 
GTx-024, Danazol or DHT induced significant increases in body weight, uterine weight 
and the surface area of the endometrial stromal and epithelial compartments  
compared to VC. Treatment with GTx-007 had no impact on these parameters.  
GTx-024, Danazol and DHT all significantly increased the percentage of Ki67-positive cells 
in the stroma, but only GTx-024 had an impact on epithelial cell proliferation. GTx-007 
significantly increased uterine expression of Wnt4 and Wnt7a, whereas GTx-024 and 
Danazol decreased their expression. In summary, the impact of GTx-024 and Danazol 
on uterine cells mirrored that of DHT, whereas GTx-007 had minimal impact on the 
tested parameters. This study has identified endpoints that have revealed differences 
in the effects of SARMs on uterine tissue and provides a template for preclinical studies 
comparing the impact of compounds targeting the AR on endometrial function.
Introduction
Androgens are pleiotropic hormones which bind with 
high affinity and specificity to androgen receptors (ARs) 
to regulate both reproductive and other tissues. In the 
uterus, androgen-target cells include stromal fibroblasts 
and epithelial cells surrounding the lumen and glands 
of the endometrium, as well as the smooth muscle cells 
of the myometrium (Simitsidellis et al. 2018). Studies in 
women and rodents have demonstrated that secretions 
from endometrial glands play a fundamental role in 
the establishment of pregnancy in both species (Filant 
& Spencer 2013, Spencer 2014, Kelleher et  al. 2018). In 
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differentiate into specialised secretory decidual cells which 
provide critical nutritional support to the early embryo 
and play a key role in regulation of trophoblast invasion 
and placental formation (Gellersen & Brosens 2014).
Over the past 20 years, there has been an increase in 
efforts to develop compounds that act via AR to promote 
and maintain the anabolic impacts of androgens on 
muscle and bone but without the undesirable side effects 
associated with exogenous androgen administration, 
including prostate hyperplasia in men or virilisation in 
women. The result of these efforts has been the synthesis 
of a new class of nonsteroidal drugs known as selective 
androgen receptor modulators (SARMs; Gao & Dalton 
2007, Mohler et al. 2009, McEwan 2013, Dalton 2017). In 
the current paper we have used a mouse model to test the 
impact of two SARMs, GTx-007 (also known as Andarine, 
S4: https://pubchem.ncbi.nlm.nih.gov/compound/ 
9824562) and GTx-024 (Enobosarm, Ostarine: https://
pubchem.ncbi.nlm.nih.gov/compound/11326715) 
on uterine tissue and to compare their activities with 
the potent, natural, non-aromatisable androgen 
dihydrotestosterone (DHT). The model chosen was 
one in which we have previously identified changes in 
gene expression and tissue function in response to DHT 
(Simitsidellis et al. 2016). Briefly, ovariectomised mice were 
administered either a single subcutaneous injection or 
seven daily injections of DHT (0.2 mg/mouse). Treatment 
with DHT resulted in a time-dependent increase in 
uterine size, characterised by an early wave of epithelial 
cell proliferation, change in the expression of genes 
encoding factors involved in stromal–epithelial cross-talk 
and a significant increase in the number of uterine glands 
in samples recovered on day 7 of treatment (Simitsidellis 
et al. 2016). In the current study, we also compared the 
impact of SARMs to Danazol (https://pubchem.ncbi.nlm.
nih.gov/compound/danazol), an orally active synthetic 
steroid derived from ethinyl testosterone, which is able to 
bind to AR and sex hormone-binding globulin (Barbieri & 
Ryan 1981). Danazol has been used since the 1970s to treat 
women with endometriosis, as well as other conditions, 
including pain associated with benign fibrocystic breast 
disease (Ramsey-Stewart 1988). Although Danazol was 
reported to be an effective treatment for endometriosis-
associated pain, androgenic side effects (acne, deepening 
of voice, hirsutism) have limited its use (Selak et al. 2007).
The development of a new generation of SARMs 
reported to have high anabolic and low androgenic 
activities has renewed interest in using them as therapeutics 
in women with muscle wasting, urinary incontinence and 
breast cancer. There have been a number of promising 
preclinical studies in rodents as well as some clinical 
trials assessing the effects of SARMs on muscle and bone. 
Specifically, in rodent models, GTx-024 has been reported 
to (1) restore pelvic floor muscle weight of ovariectomised 
mice to sham levels (Ponnusamy et al. 2017), (2) increase 
bone mineral content, bone mineral density and bone 
volume density in a rat osteoporosis model (Hoffmann 
et  al. 2019) and (3) restore levator ani muscle weight 
of orchidectomised mice to sham levels (Dubois et  al. 
2015). A phase II randomised, double-blind clinical trial 
assessing the efficacy of GTx-024 in cancer patients with 
muscle cachexia demonstrated a significant increase in 
total lean body mass of patients in the GTx-024 group 
compared to placebo (Dobs et  al. 2013). Clinical trials 
assessing the efficacy of GTx-024 for urinary incontinence 
(NCT03241342) and AR-positive triple-negative breast 
cancer (NCT01616758) are complete and release of results 
was pending at the time this manuscript was written.
GTx-007 (or Andarine) was reported to be a partial AR 
agonist able to restore total lean body mass, soleus and 
levator ani muscle mass of castrated male rats to those of 
intact animals, with minimal stimulation of the prostate 
(Gao et al. 2005). Moreover, GTx-007 significantly reduced 
ovariectomy-induced bone loss of female rats (Kearbey 
et  al. 2007) and induced a significant increase in total 
body bone mineral density, as measured by dual X-ray 
absorptiometry in castrated male rats (Gao et al. 2005).
Danazol has been used as a treatment for endometriosis 
due to its ability to generate a high androgen and low 
oestrogen environment, thus resulting in the atrophy 
of endometriotic implants and its use as a therapeutic 
agent has been demonstrated by its effectiveness in 
reducing endometriosis-associated pain and laparoscopic 
scores (Selak et  al. 2007). A Cochrane systematic review 
comparing the effects of various treatments for 
endometriosis to those of gonadotrophin‐releasing 
hormone analogues (GnRHas) on the bone mineral 
density (BMD) of women with endometriosis concluded 
that between the groups receiving GnRHa and the groups 
receiving Danazol, there was a significant difference in 
percentage change of BMD after 6 months of treatment, 
with the GnRH analogue producing a reduction in BMD 
from baseline and Danazol producing an increase in BMD 
(Sagsveen et al. 2003).
The endometrium and myometrium in women and 
mice both express AR, however, little is known about the 
impact of SARMs on the uterus. GTx-024 was reported to 
significantly increase uterine wet weight in ovariectomised 
rats (Hoffmann et  al. 2019) but to the best of our 
knowledge the impact of GTx-007 on the uterus has not 
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been investigated to date. In the current study we used a 
previously validated mouse model to assess the impact of 
SARMs on the uterus. The primary aim of this study was to 
explore changes in uterine tissue in response to treatment 
using a combination of immunohistochemistry, high-
throughput image analysis and analysis of androgen-




Female C57BL/6J mice were purchased from Charles 
River Laboratories and allowed to acclimate for a week 
with ad libitum access to food and water. Experiments 
were performed under a licence granted by the UK Home 
Office (PPL 70/8945) and were approved by the University 
of Edinburgh Animal Welfare and Ethical Review Body. 
A previously established protocol was used to assess the 
impact of androgens (Simitsidellis et al. 2016). Briefly, 8- to 
10-week-old mice were ovariectomised by dorsal bilateral 
ovariectomy and allowed to recover for 7  days prior to 
treatment, to deplete endogenous sex-steroid hormones. 
Surgery was performed under isoflurane anaesthesia 
followed by a post-operative analgesic, buprenorphine 
(0.1 mg/kg), for pain management. Ovariectomised mice 
were randomly assigned into one of five treatment groups 
(n = 10–14 per treatment group) and received seven daily 
subcutaneous injections of either vehicle control (VC; 
5% ethanol, 0.4% methylcellulose), DHT (0.2 mg/mouse), 
GTx-007 (Andarine; 0.5 mg/mouse), GTx-024 (Ostarine; 
0.5 mg/mouse) or Danazol (1.25 mg/mouse). At the time of 
tissue recovery, body weight and weights of uterine tissue 
were recorded. One uterine horn was fixed in 4% neutral 
buffered formalin (NBF) overnight at room temperature 
and the other horn was placed in RNA Save® (GeneFlow, 
Lichfield, UK) and stored at −80°C.
Histology and immunohistochemistry
Uterine tissue samples were processed according to 
standard procedures: transverse sections of 5 μm thickness 
were either stained with H&E or specific antibodies 
(Table  1) using methods detailed in Simitsidellis et  al. 
(2016). Detection was performed using a polymer-based 
detection system (ImmPRESS, Vector Labs) using the 
chromogen 3,3′-diaminobenzidine (DAB) (Vector) as per 
the manufacturer’s instructions. Between incubations, 
washes were performed with TBS-Tween. Haematoxylin 
was used as a counterstain.
Image acquisition and high-throughput  
image analysis
Stained slides were scanned using an Axio Scan.Z1 
Slidescanner (Zeiss). For quantitative image analysis, a 
minimum of two non-serial sections per animal were used 
(n = 8–14 animals/treatment group), with at least 50 μm 
distance between each cut section. High-throughput image 
analysis was performed using the StrataQuest v5.0 software 
(TissueGnostics, Vienna, Austria). Briefly, the software 
unmixes two markers (chromogen and counterstain) and 
segments single cells into nuclei, perinuclear areas and 
cytoplasm (http://www.tissuegnostics.com/en/products/
analysing-software/strataquest). Each segmented cell 
compartment is measured for up to 20 intensity, statistic 
and morphometric parameters which are displayed in 
scattergrams and histograms. For DAB-stained sections, 
negative control slides (omission of primary antibody) 
were used to set the threshold of detection. Quantification 
of FOXA2-positive endometrial glands was performed by 
blinded manual counting.
RNA extraction and reverse transcription
Total RNA was extracted from homogenised mouse 
uterine tissue (20 mg per sample) using standard methods. 
RNA concentration and quality were measured using 
a NanodropND-1000 spectrophotometer (Nanodrop 
Technologies): samples were standardised to 100 ng/μL 
in RNAse-free water. Reverse transcription was performed 
using the SuperScript VILO cDNA Synthesis Kit 
(Invitrogen) as per the manufacturer’s instructions using 
a thermal cycler programmed at 25°C for 10 min, 42°C 
for 60 min and 52°C for 5 min. Two negative controls 
(omission of reverse transcriptase control and omission of 
Table 1 Details of antibodies used for immunohistochemistry.
Protein target Antibody Supplier Catalogue number Species raised in Dilution
Androgen receptor AR Spring Bioscience M4070 Rabbit monoclonal 1/600
Marker of proliferation Ki67 MKi67 Abcam Ab15580 Rabbit polyclonal 1/2000
Forkhead box protein 2 FOXA2 Santa Cruz SC9187 Goat polyclonal 1/1000
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RNA control) were included for each set of RNA samples 
and pooled RNA from all samples was used to generate 
a ten-fold serial dilution set of standards for standard 
curve analysis.
Quantitative real-time PCR analysis
Quantitative real-time PCR (TaqMan method) was 
performed using SuperMix with Premixed ROX dye 
(Invitrogen), primer sets were designed using the 
Roche Universal Probe Library Assay Design Centre 
and purchased from Eurofins MWG Operon (Ebersberg, 
Germany) and probes from the Roche Universal Probe 
Library Mouse Set (Roche Applied Science). Samples were 
assayed in duplicate and run on an ABI 7900HT Fast Real-
Time PCR machine using the following conditions: 95°C 
for 10 minutes then 40 cycles of 95°C for 15 s and 60°C 
for 1 min. Primer amplification efficiency was validated, 
and analysis was performed using the relative standard 
curve method. Data were normalised to Actb and fold-
change is expressed as the ratio of expression of each gene 
of interest in the treated groups against the average of 
the VC groups. Statistical analysis was performed using 
GraphPad Prism 7.0. Data are presented as mean ± s.e.m. 
and statistical comparisons are described in figure legends. 
Criterion for significance was P < 0.05. Primer pair and 
probe information is provided in Supplementary Table 1 
(see section on supplementary data given at the end of 
this article).
Results
Uterine morphometric parameters are influenced by 
AR modulation
Endogenous hormones were depleted by ovariectomy 
before the start of treatments. In mice that received seven 
daily injections of DHT, GTx-024 or Danazol, significant 
increases in both body weight (Fig. 1A) and uterine weight 
(Fig. 1B) were detected compared to VC-treated mice, while 
no significant difference was detected in the GTx-007- 
treated group. On H&E-stained tissue sections, the 
impact of ovariectomy and treatments on overall uterine 
architecture was apparent (Fig.  1C). Consistent with 
depletion of ovarian hormones, ovariectomy resulted in a 
reduction in the cross-sectional surface area of the uterus, 
as well as the area occupied by the endometrial stroma and 
epithelium in the vehicle treatment group (VC) (Fig. 1C). 
Treatment with DHT, GTx-024 and Danazol all appeared 
to increase uterine area (Fig. 1C), while the uterine area in 
GTx-007-treated mice was not different from VC.
To quantify compartment-specific changes in the 
uteri of mice treated with AR modulators, image analysis 
was performed using the StrataQuest v5.0 software, which 
excluded luminal area and tissue gaps. Uterine surface area 
was significantly increased following treatment with DHT, 
GTx-024 and Danazol (Fig.  1D) mirroring the changes 
in uterine weight (Fig. 1B). The changes in total uterine 
surface area were reflected in all compartments, with DHT, 
GTx-024 and Danazol inducing expansion of the stromal, 
epithelial (luminal and glandular) and myometrial 
compartments (Fig.  1D). In contrast, treatment for 
7 days with GTx-007 resulted in uterine architecture and 
compartment measurements which appeared unchanged 
compared with VC (Fig. 1D).
Compartment-specific changes in AR expression 
induced by AR modulation
Protein levels of AR in the uteri of treated mice were 
analysed by high-throughput quantitative image analysis 
(Fig. 2A and B). Mice treated with VC exhibited low AR 
expression in all uterine compartments, with only 20% of 
stromal and glandular cells being AR positive. Treatment 
with DHT or GTx-024 significantly increased the number 
of AR-positive cells in the stroma, the glands and the 
myometrium, while Danazol-treated mice displayed no 
change in the percentage of AR-positive cells compared to 
VC in the stroma, epithelium or myometrium. Treatment 
with GTx-007 resulted in a highly heterogeneous pattern 
of AR expression in all compartments, with a significant 
increase of AR-positive cells in the luminal epithelium 
compared to VC.
Compartment-specific changes in cellular 
proliferation induced by AR modulation
The percentage of proliferating cells in uterine 
compartments was analysed by Ki67 immunostaining 
followed by high-throughput quantitative image 
analysis (Fig.  3A and B). Expression of Ki67 was 
almost undetectable in the stromal compartment and 
myometrium of VC- and GTx-007-treated mice, while 
basal levels of Ki67 expression (approximately 5–10% of 
cells) were readily detectable in the luminal and glandular 
epithelial compartments. Treatment with DHT, GTx-024 
and Danazol all significantly increased the percentage 
of Ki67-positive cells in the stromal compartment. In 
addition, GTx-024 significantly increased the percentage 
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Figure 1
Compartment-specific changes in morphometric parameters induced by AR modulation in the mouse uterus. Female C57BL/6J mice were ovariectomised 
and treated with AR ligands as described in the ‘Materials and methods’ section. (A) Changes in total body weight of treated mice between the time of 
ovariectomy and tissue collection. (B) Changes in uterine weight normalised to animal weight following treatments. (C) Representative H&E uterine 
cross-sections of treated mice are shown, with increases in uterine size being accompanied by enlargement of individual cells. (D) Cross-section of a 
mouse uterus stained with H&E. Uterine cellular compartments are highlighted (myometrium, stroma, glands (G) and luminal epithelium (LE)). Analysis of 
surface area (in mm2) of the uterus (myometrium + endometrium), the stromal compartment, the epithelial compartment (glandular + luminal) and the 
myometrium following treatments. n = 10–14/treatment group. One-way ANOVA with Tukey’s multiple comparisons test was used for comparisons 
between treatment groups. Plain stars (*) indicate comparisons with VC, while stars above lines demonstrate comparisons between indicated treatment 
groups (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). Scale bars: 500 μm. DHT, dihydrotestosterone; VC, vehicle control.
https://doi.org/10.1530/JOE-19-0153
https://joe.bioscientifica.com © 2019 The authors
Published by Bioscientifica Ltd.
Printed in Great Britain
This work is licensed under a Creative Commons 
Attribution 4.0 International License.
Downloaded from Bioscientifica.com at 08/09/2019 01:45:45PM
via University of Edinburgh
232SARMs and uterine functionI Simitsidellis et al. 242:3Journal of 
Endocrinology
of Ki67-positive cells in the glandular and luminal 
epithelium, as well as in the myometrium compared to 
VC. Notably, the percentage of proliferating cells in the 
stroma and myometrium did not exceed 5% under any of 
the treatment conditions.
GTx-024 and Danazol induce an increase in 
endometrial glands
Elegant studies in knockout mice have identified FOXA2 
as a critical endometrial gland-specific transcription 
factor and confirmed the importance of gland number in 
establishment and maintenance of pregnancy (Kelleher 
et al. 2018). To complement and extend our previous study, 
in which we detected an increase in FOXA2-positive 
glands/cross-section in mice treated with DHT for 7 days, 
we quantified numbers of glands in all treatment groups 
(Fig. 4A and B). Mice treated with either VC or GTx-007 had 
approximately ten glands per uterine cross-section within 
an endometrium, with a compact stroma, consistent with 
overall endogenous steroid depletion (Fig. 4B). Treatment 
with DHT, GTx-024 or Danazol increased the number 
of glands compared to the VC treatment group by an 
average three-fold. We had already determined that the 
area of the endometrial stroma was also significantly 
increased by these treatments (Fig.  1D) and consistent 
with this, the number of glands/endometrial area was 
similar between groups.
Figure 2
Treatment with the SARM GTx-024 altered AR 
protein levels in the uterus. (A) Uterine cross-
sections of treated mice were stained with 
immunohistochemistry for AR (brown) and were 
counterstained with haematoxylin (blue). Uterine 
compartments are indicated (luminal epithelium 
(L), glandular epithelium (G) and myometrium 
(M)). Scale bars: 100 μm. (B) High-throughput 
image analysis of AR-stained sections using 
StrataQuest revealed a significant increase in the 
percentage of AR-positive cells in all uterine 
compartments following treatment with GTx-024 
compared to VC. DHT upregulated AR in the 
stroma, glands and myometrium, while uterine 
sections of GTx-007- and Danazol-treated mice 
exhibited no change in the percentage of 
AR-positive cells compared to VC treatment. 
n = 8–14/treatment group. Kruskal–Wallis with 
Dunn’s multiple comparisons test was used for 
comparisons between treatment groups. Plain 
stars (*) indicate comparisons with VC, while stars 
above lines demonstrate comparisons between 
indicated treatment groups (*P < 0.05, **P < 0.01, 
****P < 0.0001). DHT, dihydrotestosterone; VC, 
vehicle control.
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Gene expression analysis of transcripts involved in 
stromal–epithelial cross-talk in the mouse uterus 
following treatment with AR modulators
mRNAs encoding proteins implicated in epithelial growth 
and stromal–epithelial cross-talk were measured in uterine 
tissue homogenates (endometrium plus myometrium) 
to compare the impact of SARMs and Danazol to that 
of DHT (Fig.  5). The results demonstrated clearly that 
at the concentrations administered, the impact of 
GTx-024 and Danazol on mRNA levels of analysed 
candidate genes mirrored that of DHT. These included 
a significant upregulation of the putative androgen-
regulated gene Igf1, a stromal-derived growth factor 
that is a key factor in stromal–epithelial cross-talk. 
Notably, although immuno-expression of AR was 
increased by GTx-0024 (Fig.  2), mRNA expression was 
reduced (Fig. 5), highlighting different impacts on protein 
stability and mRNA turnover. In addition, GTx-024 and 
Danazol both induced a significant reduction in the 
uterine expression of Wnt4 and Wnt7a, consistent with 
previously reported DHT-mediated effects (Simitsidellis 
et  al. 2016). The significant increase in the percentage 
of proliferating cells in the uteri of mice treated with 
DHT, GTx-024 and Danazol was reflected by a significant 
upregulation of Mki67 and downregulation of Rb1, 
together with an increase in Cdh1 (E-cadherin). Some 
differences in the effects of GTx-024, Danazol and DHT 
Figure 3
Compartment-specific effects of SARM on uterine 
cellular proliferation. (A) Uterine cross-sections of 
treated mice were stained with 
immunohistochemistry for the proliferation 
marker Ki67 (brown) and were counterstained 
with haematoxylin (blue). Scale bars: 200 μm. (B) 
High-throughput image analysis of Ki67-stained 
sections using StrataQuest revealed a significant 
increase in the percentage of Ki67-positive cells in 
the stromal compartment following treatment 
with DHT, GTx-024 and Danazol. GTx-024 
treatment induced a significant increase in the 
percentage of Ki67-positive cells in the glands and 
the myometrium, with DHT only partially 
mirroring this effect. n = 8–14/treatment group. 
Kruskal–Wallis with Dunn’s multiple comparisons 
test was used for comparisons between 
treatment groups. Plain stars (*) indicate 
comparisons with VC, while stars above lines 
demonstrate comparisons between indicated 
treatment groups (*P < 0.05, **P < 0.01, 
***P < 0.001, ****P < 0.0001). DHT, 
dihydrotestosterone; VC, vehicle control.
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were also noted, with significant upregulation of Foxa2 
only detected in DHT-treated mice, Prlr (prolactin 
receptor) only increased following treatment with 
GTx-024 and reduced expression of Ccnd1 (cyclin D1), that 
encodes a protein implicated in G1/S phase transition, 
only detected in the Danazol-treated group.
Whereas other analyses had failed to detect any 
significant impact of treatment with GTx-007 on tissue 
morphology or gland number (Figs 1 and 4) analysis of 
gene expression highlighted increased expression of 
mRNAs encoded by Wnt4 and Wnt7a, a result that was in 
marked contrast to the impact of GTx-024, which reduced 
the expression of the same mRNAs.
Discussion
The uterus is an androgen-target organ but the effects of 
SARMs, a new class of nonsteroidal drugs that are being 
tested as therapies to treat women with breast cancer, 
urinary incontinence or muscle wasting, on endometrial 
function have received little attention to date. In this 
study, we have investigated the uterine-specific effects 
of two SARMs (GTx-007 and GTx-024), compared their 
impact to those of the potent endogenous AR agonist 
DHT and to Danazol, a synthetic drug which is in clinical 
use but is reported to have androgenic side effects. We 
conducted the study using a previously established mouse 
model (Simitsidellis et  al. 2016), which was designed 
to mimic the steroid-depleted uterine environment of 
postmenopausal women, because this is a key target group 
for therapies related to restoration of muscle function.
The results obtained demonstrate that GTx-024 and 
Danazol in the mouse uterus largely mirror the impact 
of DHT, whereas GTx-007, at the supraphysiological 
dose tested, induced minimal uterine alterations. The 
significant increase in the uterine weight normalised to 
body weight of mice treated with GTx-024 is consistent 
with a rat study by Hoffmann et al. (Hoffmann et al. 2019). 
Treatment with DHT and Danazol significantly increased 
uterine weight compared to VC treatment, as previously 
reported in studies using either ovariectomised or intact 
mice (Benghuzzi & England 1995, Zhang et  al. 2004, 
Simitsidellis et  al. 2016) and rats (Lohiya & Arya 1981, 
Nantermet et al. 2005). In the current study, despite the 
significant increases in the uterine weight of mice induced 
Figure 4
Uterine stimulation by DHT, GTx-024 and Danazol 
induces glandular expansion. (A) Uterine 
cross-sections of treated mice were stained with 
immunohistochemistry for the gland-specific 
transcription factor Foxa2 (brown) and were 
counterstained with haematoxylin (blue). Scale 
bars: 500 μm. (B) Quantification of endometrial 
glands identified significant increase in the 
absolute number of glands in the endometrium 
of mice treated with DHT, GTx-024 and Danazol. 
Normalisation to endometrial area 
(epithelial + stromal) revealed that the density of 
endometrial glands is unchanged following 
treatments. n = 9–14/treatment group. One-way 
ANOVA with Tukey’s multiple comparisons test 
was used for comparisons between treatment 
groups. Plain stars (*) indicate comparisons with 
VC, while stars above lines demonstrate 
comparisons between indicated treatment groups 
(*P < 0.05, **P < 0.01, ***P < 0.001). DHT, 
dihydrotestosterone; VC, vehicle control.
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by DHT (~60 mg), GTx-024 (~47 mg) and Danazol (~46 mg) 
compared to VC (~22 mg), uterine weight values were still 
considerably lower than those of intact aged-matched 
female C57BL/6J mice (~70 mg). This demonstrates these 
AR ligands can induce restoration of the steroid-depleted 
uterus, but that this increase in uterine weight does not 
exceed that of the normal cycling uterus. Notably, two 
other SARMs, MK-0773 and TFM-4AS-1, both of which 
bind AR in vitro, can induce only modest weight gains in 
the uterus of ovariectomised rats after 24 days of treatment 
(Schmidt et al. 2010). In addition, the uterus has an outer 
layer, the myometrium which is made up of smooth 
muscle cells and in the context of this study provided 
an additional endpoint for the impact of the ligands on 
smooth muscle. Our previous studies have documented 
expression of AR in mouse myometrium (Makieva et al. 
2016) and in this study, DHT, GTx-024 and Danazol all 
significantly increased myometrial area.
In the endometrium, GTx-024 exhibited a trophic 
effect, increasing the area of both the stromal and 
epithelial compartments, a result consistent with 
increased percentage of Ki67-positive nuclei in both cell 
types. While the mechanistic basis for these changes 
was not studied, it is notable that GTx-024, in common 
with DHT, significantly increased the expression of 
Igf1. IGF1 acts as an anabolic growth factor in skeletal 
muscle, stimulating the PI3K/Akt signalling pathway to 
increase protein synthesis, reduce protein degradation 
and increase muscle mass (Timmer et  al. 2018). In the 
endometrium, IGF1 is a stromal-derived growth factor that 
binds to the IGF1 receptor on epithelial cells, indirectly 
mediating the proliferative effects of 17β-oestradiol on 
epithelial cells (Zhu & Pollard 2007). Consistent with 
GTx-024 and DHT acting by binding to AR to increase 
the expression of Igf1, androgen response elements (AREs) 
have been documented on the promoter of the IGF1 
Figure 5
Whole-uterus gene expression changes of 
proteins involved in proliferation and stromal–
epithelial cross-talk. Gene expression analysis by 
RT-qPCR of mRNAs extracted from whole-uterine 
homogenates of mice treated with AR ligands; 
individual genes are identified above the relevant 
results panels. n = 10–14/treatment group. 
One-way ANOVA with Tukey’s multiple 
comparisons test was used for comparisons 
between treatment groups. Plain stars (*) indicate 
comparisons with VC, while stars above lines 
demonstrate comparisons between indicated 
treatment groups (*P < 0.05, **P < 0.01, 
***P < 0.001, ****P < 0.0001). DHT, 
dihydrotestosterone; VC, vehicle control.
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gene in humans (Wu et  al. 2007). Notably, IGF1 is also 
upregulated in women with PCOS, a condition often 
associated with hyperandrogenism (Shafiee et  al. 2016). 
A recent publication using the SARM S-42 (Patent No. 
5789874, Japan) reported an increase in the weight of the 
levator ani muscle in rats but failed to detect any change 
in Igf1 mRNA when it was used to treat cultured mouse 
C2C12 myoblasts (Muta et  al. 2019). Notably, we have 
previously demonstrated that muscle-resident AR-positive 
fibroblasts could mediate indirect effects of both GTx-024 
and DHT on the levator ani muscle (Dubois et al. 2015), 
highlighting the importance of studying the impact of 
SARMs on intact tissue as well as isolated cells.
Using the 7-day treatment regime, we noted broadly 
similar uterine impacts of GTx-024 and Danazol, 
including significant changes in uterine weight and 
architecture, although in contrast to GTx-024, Danazol 
had no significant impact on AR protein levels. With 
some exceptions, the general consensus is that androgens 
tend to downregulate the expression of their receptor 
at the transcriptional level (Quarmby et  al. 1990, Shan 
et  al. 1990, Prins & Woodham 1995, Yeap et  al. 1999), 
but stabilise the AR protein (Krongrad et  al. 1991, Yeap 
et al. 1999) and our results with GTx-024 are consistent 
with this.
To date, the majority of clinical trials assessing the 
efficacy of SARMs have used GTx-024, reflecting some 
of the promising results obtained in preclinical studies, 
with several focusing on improving muscle function, 
including that in postmenopausal women (ten trials 
listed). Some phase II trials have reported promising 
findings regarding the therapeutic potential of GTx-024, 
including a statistically significant improvement in total 
lean body mass and physical function at 3 mg/day for 
86  days in postmenopausal women, without reported 
impacts on sebum production or hair growth (Dalton 
et  al. 2011). The phase III clinical trials (POWER1 and 
POWER2) assessing efficacy of GTx-024 in the prevention 
and treatment of muscle wasting of non-small-cell 
lung cancer patients failed to demonstrate significant 
improvement in physical function, despite significant 
increases in lean body mass (Crawford et al. 2016) (the 
results of the POWER trials are not yet in published 
form; clinical trial number NCT01355484). A recent 
phase II trial which focused on assessing safety and 
tolerability in postmenopausal women suffering from 
stress incontinence (n = 129) was terminated in October 
2018 citing lack of efficacy (NCT03566290), which is of 
concern for the future of SARMs usage for this common 
clinical manifestation.
The GTx-007 compound was developed as a treatment 
for muscle wasting and benign prostatic hyperplasia, but 
the impacts of the compound on females remain largely 
unexplored. In one study, 0.1–3 mg/day of GTx-007 were 
administered to ovariectomised female rats for 120 days, 
with the authors reporting the doses were based on 
unpublished pilot data. Results were compared to those 
obtained using 1 mg/day of DHT (Kearbey et  al. 2007). 
The authors reported that GTx-007 had a dose-dependent 
increase in body weight, lean mass and bone strength. 
In our study, we did not detect any impact of GTx-007 
on body weight or myometrial area, with GTx-007 also 
displaying minimal uterine effects. In castrated male rats, 
GTx-007 shows dose-dependent effects in the levator 
ani muscle; however, GTx-007 is only a partial agonist 
in the prostate and seminal vesicles, restoring them to 
33.8 and 28.2% of intact animals, respectively (Yin et al. 
2003). Based on our findings, we speculated this might 
be the case in the uterus, with GTx-007 acting as a partial 
agonist, but this warrants further investigation.
Gene expression analysis revealed changes in the 
expression of Wnt4 and Wnt7a in the uteri of treated 
mice. Wnt proteins play a key role in stromal–epithelial 
interactions within the uterus, with studies in mice 
demonstrating expression of Wnt4 predominantly in 
the endometrial subluminal stromal compartment and 
Wnt7a in the luminal epithelium (Miller et al. 1998). Wnts 
in the uterus are involved in tissue patterning during 
postnatal organ development and regulate uterine gland 
formation, a process termed adenogenesis, with Wnt4 
and Wnt7a uterine-knockout mice exhibiting absence of 
glands due to defective postnatal endometrial epithelial 
differentiation accompanied by defects in fertility and 
disrupted expression of genes involved in decidualisation 
of the endometrium, such as Hoxa10 and Lif (Dunlap 
et al. 2011, Franco et al. 2011). In our previous study, we 
noted a significant decrease in Wnt4 and Wnt7a uterine 
expression in response to DHT treatment (Simitsidellis 
et  al. 2016), a finding that was replicated here and 
mirrored by treatment with GTx-024 and Danazol. In 
contrast, treatment with GTx-007 induced a modest but 
significant upregulation of Wnt4 and Wnt7a in the uteri 
of treated mice.
Our study was designed to detect impacts on 
the mouse uterus and had a number of limitations: 
(1) dosage of treatments was supraphysiological, (2) only 
one time point was selected for analysis of samples and 
(3) differences in the impacts of high-dose androgens on 
uterine architecture between rodents and primates have 
been reported. (1) For this study, we selected doses of AR 
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ligands previously shown to induce significant uterine 
changes in mice and rats but that do not reflect their 
physiological or therapeutic concentrations (Nantermet 
et al. 2005, Ivanga et al. 2009, Simitsidellis et al. 2016). 
However, a study by Hoffmann et  al. demonstrated 
that even a dose as low as 0.4 mg/kg/day of GTx-024 
can elicit a significant increase in uterine wet weight 
of ovariectomised mice, restoring uterine weight to 
that of intact mice if treatment continues for 5  weeks 
(Hoffmann et al. 2019), suggesting that the trophic effects 
of androgens in the rodent uterus are not just a result 
of high androgen concentrations. (2) We previously 
reported that treatment of ovariectomised mice with 
DHT induces an early proliferative response in the uterus 
at 24 h of treatment, followed by a late uterotrophic 
phenotype after 7 days of treatment (Simitsidellis et  al. 
2016). In the current study, only the 7-day time point 
was used for comparative analysis. (3) Importantly, the 
majority of studies have reported long-term androgen 
administration at high doses to women and transmen 
can induce endometrial atrophy (Chadha et  al. 1994, 
Perrone et  al. 2009) without stimulating endometrial 
proliferation (Zang et  al. 2007, Wood et  al. 2009, 
Simitsidellis et al. 2018). However, a recent report on 94 
transmasculine persons given testosterone demonstrated 
that there was persistence of endometrial activity in 67% 
of the subjects, highlighting the potential for variation 
in the response of individuals to high doses of androgens 
(Grimstad et al. 2019). In the current study as in others, 
administering androgens to ovariectomised rodents, 
treatment with DHT, GTx-024 or Danazol increased the 
percentage of Ki67-positive cells in the stroma and had a 
variable impact on epithelial cell proliferation. Our data 
suggest caution should be exercised when extrapolating 
rodent uterotrophic effects of androgens to humans 
and highlights the need for further investigations using 
different models such as human endometrial tissue 
explants for the evaluation of SARMs.
We included Danazol, a synthetic derivative of 
testosterone which is reported to be an effective treatment 
for endometriosis-associated pain in this study as a 
comparator to the SARMs and in anticipation that the 
latter might be used to treat women with endometriosis. 
Danazol’s mechanism of action is complex, but it is 
reported to both directly and indirectly reduce ovarian 
steroidogenesis so that in women with endometriosis 
both eutopic and ectopic endometrium becomes inactive 
(Selak et  al. 2007). While Danazol continues to be 
prescribed to some women with endometriosis for which 
other therapies have failed, it is not recommended for 
women wishing to become pregnant, due to side effects 
associated with its androgenic activity (https://bnf.
nice.org.uk/drug/danazol.html). In our model, Danazol 
induced an uterotrophic response which was similar to 
that of DHT a result consistent with reports that it can 
bind with high affinity to AR.
To date, there have been no reports of adverse 
androgenic side effects of GTx-024 in women, but these 
would need to be revisted in future studies should the 
SARM be evaluated in trials for treatment of women with 
endometriosis. Notably, our findings and those of others, 
have demonstrated that in rodents while treatment with 
DHT or GTx-024 can induce an increase in uterine weight, 
this only leads to a restoration of the uterine weight of 
steroid-depleted animals to that of intact animals. New 
SARMs are still in development, but there is limited 
information about their use in women. One exception 
is GSK2881078, which showed promising results in a 
phase Ib trial, with doses of up to 0.75 mg/day tested for 
their impact on muscle weakness (Neil et al. 2018). This 
compound was found to have a long half-life in women 
and lean mass was shown to increase, with women being 
much more sensitive to lower doses than men highlighting 
potential sex differences in response.
In summary, administration of the SARM GTx-024 
resulted in uterotrophic changes that mimicked those of 
DHT whereas GTX-007, a SARM with a similar but not 
identical structure, had little impact. Both SARMs exhibit 
similar binding to AR in cell-based models highlighting 
the importance of tissue-based analysis. The development 
of SARMs with differing impacts on uterine function 
may offer new therapeutic opportunities for treatment 
of disorders associated with muscle wasting in women. 
Based on these results, it is clear that further studies are 
required to inform choice of therapeutic doses that can be 
evaluated in clinical trials.
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